Can you help us learn more about the body’s immune response to COVID-19 vaccines?
The Platform Trial In COVID-19 Vaccine BOOsting (PICOBOO) Study is designed to evaluate the comparative effectiveness of COVID-19 booster vaccines.
Telethon Kids Institute researchers are working with study sites around Australia to see what effect COVID-19 booster vaccination has on the immune system, how long these effects last, and what the optimal booster strategies are for people living in Australia. The study will also explore the safety of booster vaccination and how well boosting protects against hospitalisation and disease.
Your participation in the PICOBOO Study will help researchers develop the most effective, long-term strategies for COVID-19 booster vaccinations nation-wide.
What does the study involve?
Participation in the PICOBOO Study will take place over a two-year period and involve six visits to the research clinic at Perth Children's Hospital. These appointments will include:
immunisation with an approved COVID-19 booster vaccine
providing blood and saliva samples to test for an individual's immune response before they receive their vaccine and at five additional time points over the study period
completing regular SMS surveys
Are you eligible to participate?
Study researchers are urgently calling for the following participants:
Adults aged 50 or over who have already received three COVID-19 vaccinations and are interested in having a second booster dose.
Teenagers aged 12 - 17 who have received two COVID-19 vaccinations and would like to be one of the first in this age group to have a booster dose.
Adults of all ages who have received their first two COVID-19 vaccinations but have not yet had their first booster dose. Eligible participants must have had two doses of Pfizer Comirnaty or two doses of COVID-19 Vaccine Astra Zeneca to take part.
This study has been approved by the Child and Adolescent Human Research Ethics Committee. Any person with concerns or complaints about the conduct of this study should contact the Executive Director Medical Services via [08 6456 2222] who can refer your concerns to the HREC monitoring the project.
If you'd like to get in touch, please contact us by phone or email.